Skip to main navigation Skip to search Skip to main content

Breakthrough Aspergillus fiimigatus and Candida albicans double infection during caspoftingin treatment: Laboratory characteristics and implication for susceptibility testing

  • Maiken Cavling Arendrup
  • , Guillermo Garcia-Effron
  • , Walter Buzina
  • , Klaus Leth Mortensen
  • , Nanna Reiter
  • , Christian Lundin
  • , Henrik Elvang Jensen
  • , Cornelia Lass-Florl
  • , David S. Perlin
  • , Brita Bruun
  • Statens Serum Institut
  • Public Health Research Institute, New York
  • Medical University of Graz
  • Roskilde Hospital
  • University of Copenhagen
  • Innsbruck Medical University

Research output: Contribution to journal › Article › peer-review

118 Scopus citations

Abstract

Caspofungin is used for the treatment of acute invasive candidiasis and as salvage treatment for invasive aspergillosis. We report characteristics of isolates of Candida albicans and Aspergillus fumigatus detected in a patient with breakthrough infection complicating severe gastrointestinal surgery and evaluate the capability of susceptibility methods to identify candin resistance. The susceptibility of C. albicans to caspofungin and anidulafungin was investigated by Etest, microdilution (European Committee on Antibiotic Susceptibility Testing [EUCAST] and CLSI), disk diffusion, agar dilution, and FKS1 sequencing and in a mouse model. Tissue was examined by immunohistochemistry, PCR, and sequencing for the presence of A. fumigatus and resistance mutations. The MICs for the C. albicans isolate were as follows: >32 μg/ml caspofungin and 0.5 uμg/ml anidulafungin by Etest, 2 uμg/ml caspofungin and 0.125 uμg/ml anidulafungin by EUCAST methods, and 1 uμg/ml caspofungin and 0.5 uμg/ml anidulafungin by CLSI methods. Sequencing of the FKS1 gene revealed a mutation leading to an S645P substitution. Caspofungin and anidulafungin failed to reduce kidney CFU counts in animals inoculated with this isolate (P > 0.05 compared to untreated control animals), while both candins completely sterilized the kidneys in animals infected with a control isolate. Disk diffusion and agar dilution methods clearly separated the two isolates. Immunohistochemistry and sequencing confirmed the presence of A. fumigatus without FSK1 resistance mutations in liver and lung tissues. Breakthrough disseminated aspergillosis and candidiasis developed despite an absence of characteristic FKS1 resistance mutations in the Aspergillus isolates. EUCAST and CLSI methodology did not separate the candin-resistant clinical isolate from the sensitive control isolate as well as did the Etest and agar methods.

Original languageEnglish
Pages (from-to)1185-1193
Number of pages9
JournalAntimicrobial Agents and Chemotherapy
Volume53
Issue number3
DOIs
StatePublished - Mar 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Breakthrough Aspergillus fiimigatus and Candida albicans double infection during caspoftingin treatment: Laboratory characteristics and implication for susceptibility testing'. Together they form a unique fingerprint.

Cite this